Which manufacturer produces Belumosudil tablets and what is the quality?

Belumosudil mesylate tablets (Belumosudil) are manufactured by Kadmon Pharmaceuticals, LLC, A SANOFI COMPANY. Kadmon Pharmaceuticals is a global biopharmaceutical company dedicated to developing and commercializing innovative therapeutics with a primary focus on oncology, immunology and other disease areas. Besudil is an immunosuppressant designed to treat chronic graft-versus-host disease (cGVHD), especially in patients who are refractory to conventional treatments.

The quality of Besudil has been recognized by the global medical community, especiallyKadmon Pharmaceuticals' strict standards in drug development and production. As part of Sanofi, Kadmon has access to Sanofi's global resources and quality management system, which provides a strong guarantee for the production quality of Besudil. The production of Besudil complies with the relevant regulations of the U.S. Food and Drug Administration (FDA) and other international agencies, ensuring the safety and effectiveness of the drug during treatment.

Besudil is a targeted treatment drug for chronic graft-versus-host disease. Multiple international studies and clinical trials have proven its safety and efficacy. Therefore, in terms of quality, Besudil tablets have been widely recognized and become an innovative drug in this field.

In general, the launch of besudil provides an important treatment option for patients with chronicGVHD and has attracted the attention of the global medical community. Besudil is of reliable quality and has been proven effective in the treatment of chronic graft-versus-host disease through rigorous clinical validation. During the treatment process, patients can expect better results under the guidance of their doctor. For clinicians, Kadmon's strict quality control system and mature production process are also important reasons for choosing Besudil as a treatment drug.

Reference: https://www.drugs.com/pro/rezurock.html